header
朱海珍

发布于:2018-10-17 星期三 21:42:30 点击数:3331

1.png 

朱海珍

教授、博士生导师、教育部新世纪优秀人才、系主任

Tel:88821385

E-mail:zhuhaizhen69@yahoo.com


基本信息

朱海珍:医学博士,教授,博士生和硕士生导师。

1990、1997年分别毕业于白求恩医科大学、同济医科大学,分别获得医学学士、医学硕士学位,2000年毕业于华中科技大学同济医学院,获得医学博士学位。2000-2005年在美国佛罗里达大学医学院病理学、免疫学和实验医学系从事博士后研究工作,2005-2009年任美国佛罗里达大学医学院的Assistant Scientist。自2008年起任湖南大学教授,2010起兼任湖南省肿瘤医院(现中南大学湘雅医学院附属肿瘤医院)教授,2009年教育部新世纪优秀人才支持计划获得者。2014年参加国家杰出青年科学基金答辩。

主要从事肿瘤学、微生物学、免疫学、分子生物学和细胞生物学领域的教学和科研工作。具体研究内容包括肿瘤细胞信号传导与免疫调节机制、病毒与宿主的相互作用、肿瘤细胞与病毒的免疫逃逸机制,以及恶性肿瘤和肝炎的生物治疗靶向药物、肿瘤免疫治疗药物与疫苗的研发。

主持承担国家科技重大专项、国家自然科学基金重点项目和面上项目等多项科研项目,完成了美国国家卫生研究院资助的多项科研项目。在PNAS、Gastroenterology、Hepatology、Journal of Virology等国际著名学术刊物上发表90余篇学术论文,其中多篇论文被撰写述评和作为研究亮点报道。Frontier in Immunology、Annals of Infectious Disease and Epidemiology等期刊编委,Oncotarget、FEBS Letter、Laboratory Investigation、Journal of Medical Virology、PLoS ONE、Virology Journal等期刊审稿人。多次应邀在国内外学术会议上作特邀报告。获得1项美国发明专利并授权,申请了另一项美国、欧盟和日本发明专利,已获美国和欧盟发明专利授权,获得6项国家发明专利。获得1项湖南省科技进步奖和1项湖南省医学科技奖。

 

课程名称:药理学课程英文名:Pharmacology
学时/学分:32/2适合专业:生物技术、生物医学工程
专业性质:本科生课程编号:0
课程简介:进入课程主页

课程名称:专业英语课程英文名:Scientific English
学时/学分:32/2适合专业:生物医学工程
专业性质:研究生课程编号:0
课程简介:进入课程主页

课程名称:生命科学导论课程英文名:Introduction to Life Science
学时/学分:32/2适合专业:
专业性质:本科生通识课课程编号:0
课程简介:进入课程主页

课程名称:生命科学前沿课程英文名:
学时/学分:32/2适合专业:生物技术
专业性质:必修课课程编号:0
课程简介:进入课程主页





教育背景

1990年毕业于白求恩医科大学,获得医学学士

1997年毕业于同济医科大学,医学硕士学位

2000年毕业于华中科技大学同济医学院,获得医学博士学位

学术兼职

兼任湖南省肿瘤医院(现中南大学湘雅医学院附属肿瘤医院)教授

Frontier in Immunology、Annals of Infectious Disease and Epidemiology等期刊编委

Oncotarget、FEBS Letter、Laboratory Investigation、Journal of Medical Virology、PLoS ONE、Virology Journal等期刊审稿人

研究领域

主要从事肿瘤学、微生物学、免疫学、分子生物学和细胞生物学领域的教学和科研工作。具体研究内容包括肿瘤细胞信号传导与免疫调节机制、病毒与宿主的相互作用、肿瘤细胞与病毒的免疫逃逸机制,以及恶性肿瘤和肝炎的生物治疗靶向药物、肿瘤免疫治疗药物与疫苗的研发。

联系方式:0731-88821385;hzzhu@hnu.edu.cn,   zhuhaizhen69@yahoo.com


学术成果

1. Xu C, Yang D, Mei L, Lu B, Chen L, Li Q, Zhu H, Wang TH.Encapsulating gold nanoparticles or nanorods in grapheme oxide shell as a novel gene vector. ACS Appl Mater Interfaces 2013; 5:2715-2724.

2. Yang D, Liu N, Zuo C, Lei S, Wu X, Zhou F, Liu C, Zhu H. Innate immune    response of primary human hepatocytes with hepatitis C viralinfection.PLoS  One 2011; 6(11):e27552

3. Meng L, Yang L, Zhao X, Zhang L, Zhu H, Liu C, Tan W. Targeted delivery of chemotherapy agents using a liver cancer-specific aptamer. PLoS One 2012; 7(4):e33434

4. Tan W, Wang H, Chen Y, Zhang X, Zhu H, Yang C, Yang R, Liu C. Molecular aptamers for drug delivery. Trends Biotechnol 2011; 29:634-640

5. Eksioglu EA, Zhu H, Bayouth L, Bess J, Liu HY, Nelson DR, Liu C. Characterization of HCV interactions with Toll-like receptors and RIG-I in liver cells. PLoS One 2011; 6(6):e21186

6. Zhao X, Cao M, Liu JJ, Zhu H, Nelson DR, Liu C. Reactive oxygen species is essential for cycloheximide to sensitize lexatumumab-induced apoptosis in hepatocellular carcinoma cells. PLoS One 2011; 6(2):e16966

7. Yao L, Dong H, Zhu H, Nelson DR, Liu C, Lambiase L, Li X. Identification of IFITM3 gene as an inhibitors of hepatitis C viral translation in a stable STAT1 cell line. J Viral Hepat 2011; 18:e523-e529

8. Eksioglu EA, Bess J, Zhu H, Xu Y, Dong H, Elyar J, Nelson DR, Liu C. Hepatitis C virus modulates human monocyte-derived dendritic cells. J Viral Hepat 2010; 17:757-769

9. Eksioglu EA, Bess J, Jones G, Dettloff J, Dangmeon P, Dong HJ, Zhu H, Firpi R, Xu Y, Nelson DR, Liu C. Characterization of anti-HCV antibodies in IL-10 treated patients. Viral Immunology 2010;23:359-368

10. Zhu H, Elyar J, Foss R, Hemming A, Hall E, Lecluyse EL, Liu C. Primary human hepatocyte culture for HCV study. Methods Mol Biol, 2009 510:373-382
11. Kenworthy R, Lambert D, Yang F, Wang N, Chen Z, Zhu H, Zhu F, Liu C, Li K, Tang H. Short-hairpin RNAs delivered by lentiviral vector transduction trigger RIG-I-mediated IFN activation. Nucleic Acids Res.2009;37:6587-6599

12. Wu H, Zhu H, Zhuang J, Liu C, Cao YC. Water-soluble nanocrystals through dual-interaction ligands. Angew Chem Int Edit. 2008; 47:3730-34

13. Li C, Long Y, Liu B, Xiang D, Zhu H. Real-time monitoring uracil excision using uracil-containing molecular beacons. Anal Chim Acta 2014; 819:71-77.

14. Butler SL, Dong H, Cardona D, Jia M, Zheng R, Zhu H, Crawford JM, Liu C. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest 2008; 88:78-88

15. Zhu H, Dong H, Eksioglu E, Hemming A, Cao M, Crawford CM, Nelson DR, Liu C. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology 2007; 133:1649-1659

16. Liu C, Zhu H, Subramanian MG, Moore PA, Xu Y, Nelson DR. Anti-hepatitis C virus activity of albinterferon alfa-2b in cell culture. Hepatology Research. 2007; 37:941-947

17. Cao M, Cabrera R, Xu Y, Firpi R, Zhu H, Liu C, Nelson DR. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells. Lab Invest. 2007, 87:582-590

18. *Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Reed AI, Liu C, Nelson DR. Cyclosporine suppresses hepatitis C virus in vitro and increase the chance of sustained virological response after liver transplantation. Liver Transplantation 2006, 12:51-57 (see Editorial on Page 19-21)

19. Zhu H, Butera M, Nelson DR and Liu C. Novel type I Interferon IL-28A suppresses hepatitis C viral RNA replication. Virology J  2005, 2:80

20. Zhu H, Nelson DR, Crawford JM and Liu C. Defective JAK-STAT activation in host cells confers hepatitis C viral interferon-alpha resistance. J of Interferon and Cytokine Res 2005, 25(9): 528-539

21. Rufforny I, Wilkinson EJ, Liu C, Zhu H, Buteral M, Massoll NA. Human papillomavirus infection and p16 (INK4a) protein expression in vulvar intraepithelial neoplasia and invasive squamous cell carcinoma. J Lower Genital Tract Disease. 2005, 9(2):108-113

22. Zhu H, Shang X, Terada N, Liu C. STAT3 induces anti-hepatitis C viral activity in liver cells. Biochem and Biophys Res Commun 2004; 324:518-528

23. Shang XZ, Zhu H, Lin K, Tu Z, Chen J, Nelson DR and Liu C. Stabilized b-catenin promotes hepatocyte proliferation and inhibits TNFa-induced apoptosis. Laboratory Investigation 2004; 84:332-341

24. Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu YL, Cabrera R, Liu C and Davis G. Long-term interleukin10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003; 38:859-868

25. *Liu C, Zhu H, Tu Z, Xu YL and Nelson DR. CD8+ T cell interaction with HCV replicon cells: evidence for both cytokine- and cell—mediated antiviral activity. Hepatology 2003; 37:1335-1342 (Highlights on Hepatology 2003; 38:1-3)

26. *Zhu H, Zhao H, Collins CD, Eckerrode SE, Ruan Q, Mcindoe RA, Crawford JM, Nelson DR, She JX and Liu C. Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology 2003; 37:1180-1188 (see Editorial on Page 975-978)(Highlights on Hepatology 2003; 38:1-3)

27. Zhu H and Liu C. Interleukin-1 inhibit hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway. J Virology 2003; 77:5493-5498

28. Xiao H, Xie P, Zhou K, Qiu X, Hong Y, Liu J, Ouyang Y, Ming T, Xie H, Wang X, Zhu H, Xia M, Zuo C. Clavien-Dindo classification and risk factors of gastrectomy-related complications: an analysis of 1049 patients. Int J Clin Exp Med 2015; 8(5):8262-8288

29. Yang D, Meng X, Yu Q, Xu L, Long Y, Liu B, Fang X, Zhu H. Inhibition of hepatitis C virus infection by DNA aptamer against envelop protein. Antimicrob Agents and Chemother 2013; 57(10):4937-4944

30. Yang D, Xue B, Wang X, Yu X, Liu N, Gao Y, Liu C, Zhu H. 2-Octynoic acid inhibits hepatitis C virus infection through activation of AMP-activated Protein Kinase. PLoS One 2013; 8:e64932
31. Zuo C, Xia M, Wu Q, Zhu H, Liu J, Liu C. Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection. Oncol Lett 2015; 9:527-534.

32. Xu C, Yang D, Mei L, Li Q, Zhu H, Wang TH. Targeting chemo-photothermal therapy of hepatoma by gold nanorods/graphene oxide core/shell nanocomposites. ACS Appl Mater Interfaces 2013; 5:12911-12920

33. Gao Y, Yu X, Xue B, Zhou F, Wang X, Yang D, Liu N, Xu L, Fang X, Zhu H. Inhibition of hepatitis C virus infection by DNA aptamer against NS2 Protein. PLoS ONE 2014; 9:e90333

34. Shi S, Yu X, Gao Y, Xue B, Wu X, Wang X, Yang D, Zhu H. Inhibition of hepatitis C virus production by aptamer for core protein. J Virol 2014;88(4):1990-1999

35. Yang D, Zuo C, Wang X, Meng X, Xue B, Liu N, Yu R, Qin Y, Gao Y, Wang Q, Hu J, Wang L, Zhou Z, Liu B, Tan D, Guang Y, Zhu H. Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line. Proc Natl Acad Sci USA 2014; 111(13):E1264-1273 (Highlights in PNAS 2014; 111(13):4735-4736) (Highlighted by Nature/SciBX in SciBX 7(11); doi:10.1038/scibx.2014.325)

36. Yang D. Meng X, Xue B, Liu N, Wang X, Zhu H. MiR-942 mediates hepatitis C virus-induced apoptosis via regulation of ISG12a. PLoS ONE 2014;9(4):e94501

37. Yu X, Gao Y, Xue B, Wang X, Yang D, Qin Y, Yu R, Liu N, Xu L, Fang X, Zhu H. Inhibition of hepatitis C virus infection by NS5A-specific aptamer. Antiviral Res 2014; 106:116-124

38. Liu N, Long Y, Liu B, Yang D, Li C, Chen T, Wang X, Liu C, Zhu H*. ISG12a mediates cell response to Newcastle disease viral infection. Virology 2014; 462-463C:283-294

39. Liu N, Zuo C, Wang X, Chen T, Yang D, Wang J, Zhu H*. miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT. Oncotarget 2014

40. Zuo CH, Qiu XX, Ouyang YZ, Zhang D, Xiao H, Mo SC, Tan CQ, Tang M, Zhu H. Mesohepatectomy for the treatment of patients with centrally located hepatocellular carcinoma. Mol Clin Oncol 2014; 2:833-838.
41. Zuo CH, Xia M, Liu JS, Qiu XX, Lei X, Xu RC, Liu HC, Li JL, Li YG, Li QL, Xiao H, Hong Y, Wang XH, Zhu HZ, Wu QF, Burns M, Liu C. Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection. Asian Pac J Cancer Prev 2015; 16(1):245-51.

42. Zuo C, Qiu X, Liu N, Yang D, Man X, Liu J, Wang X, Zhu H, Xie H, Xie P, Burns M, Liu C. Interferon-α and cyclooxygenase-2 inhibitor cooperatively mediates TRAIL-induced apoptosis in hepatocellular carcinoma. Exp Cell Res 2015; 333:316-326.

43. Yang DR, Zhu HZ*. Hepatitis C virus and antiviral innate immunity: Who wins at tug-of-war?(Invited Review) World J Gatroenterol 2015; 21:3786-3800.

44. Liu N, Chen T, Wang X, Yang D, Xue B, Zhu H*. Msi1 confers resistance to TRAIL by activating ERK in liver cancer cells. FEBS Lett 2015; 589:897-903.

45. Yu R, Yang D, Lei S, Wang X, Meng X, Xue B, Zhu H*. HMGB1 promotes hepatitis C virus replication by interaction with stem-loop 4 in the viral 5′ untranslated region. J Virol 2016; 90(5):2332-2344.

46. Meng X, Yang D, Yu R, Zhu H*. EPSTI1 is involved in IL-28-mediated inhibition of HCV infection. Mediators of Inflammation 2015; 2015:716315.

47. Xue B, Yang D, Wang J, Xu Y, Wang X, Qin Y, Tian R, Chen S, Xie Q, Liu N, Zhu H*. ISG12a restricts hepatitis C virus infection through the ubiquitination-dependent degradation pathway. J Virol 2016; 90(15):6832-6845 (Spotlight in J Virol 2016; 90(15):6611).

48. Qin Y, Xue B, Liu C, Wang X, Tian R, Xie Q, Guo M, Li G, Yang D*, Zhu H*. NLRX1 mediates MAVS degradation to attenuate hepatitis C virus-induced innate immune response through PCBP2. J Virol 2017; 91(23):e01264-17 (Spotlight in J Virol 2017; 91(23):e01746-17).

49. Zhou K, Xia M, Tang B, Yang D, Liu N, Tang D, Xie H, Wang X, Zhu H, Liu C, Zuo C. Isolation and comparison of mesenchymal stem-cell like cells derived from human gastric cancer tissues and corresponding ovarian metastases. Mol Med Rep 2016; 13(2):1788-1794

50. Xiao H, Xie P, Zhou K, Qiu X, Hong Y, Liu J, Ouyang Y, Ming T, Xie H, Wang X, Zhu H, Xia M, Zuo C. Clavien-Dindo classification and risk factors of gastrectomy-related complications: an analysis of 1049 patients. Int J Clin Exp Med 2015; 8(5):8262-8288
51. Qiu X, Hong Y, Yang D, Xia M, Zhu H, Li Q, Xie H, Wu Q, Liu C, Zuo C. ISG15 as a novel prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma. Int J Clin Exp Med 2015; 8(10):17140-17150

52. Wu Z, Tan S, Xu L, Gao L, Zhu H, Ma C, Liang X. NgAgo-gDNA system efficiently suppresses hepatitis B virus replication through accelerating decay of pregenomic RNA. Antiviral Res 2017; 145:20-23.

53. Liu N, Zuo C, Wang X, Chen T, Yang D, Wang J, Zhu H*. miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT. Oncotarget 2014; 5:4959-4971.